Nader Z. Pourhassan, Ph.D.
President and CEO
Dr. Pourhassan was appointed a Director in September 2012 and has served as CytoDyn’s President and Chief Executive Officer since December 2012. Prior to that, he was the Company’s Managing Director of Business Development from June 2011 to December 2012, and Chief Operating Officer from May 2008 to June 2011. Dr. Pourhassan was responsible for identifying the opportunity with PRO 140 and instrumental in the acquisition of this asset. He has overseen the rapid clinical development of PRO 140 as a therapy for HIV from Phase 2 development and into Phase 3 trials including the development of trial protocols and interaction with the U.S. Food and Drug Administration (FDA). He also has been involved in preclinical and clinical development of PRO 140 in additional immunological indications. Dr. Pourhassan has led CytoDyn’s capital market activities since joining the Company in 2008. He has more than 20 years of business development experience. Dr. Pourhassan received his Bachelor of Science from Utah State University in 1985, his Masters of Science from Brigham Young University in 1990 and his Ph.D. in Mechanical Engineering from the University of Utah in 1998. Dr. Pourhassan has authored three books.
Michael D. Mulholland
Chief Financial Officer, Treasurer and Corporate Secretary
Mr. Mulholland brings to CytoDyn more than 25 years of senior level financial leadership for public companies in the business services, retail and manufacturing industries. His broad experience includes strategic planning, corporate finance, including raising debt and equity capital, acquisitions, corporate restructurings, SEC reporting, risk management, investor relations and corporate governance matters. In addition to his financial management experience, Mr. Mulholland has also managed IP-asset development for the chemical inventions of a leading European scientific inventor for improving human health, working with IP counsel to evaluate and prosecute domestic and foreign patent applications. Most recently, from 2011-2012, he served as Chief Financial Officer of Nautilus, Inc., a NYSE-listed developer and marketer of fitness equipment. He previously was Co-Chief Financial Officer of Corporate Management Advisors, Inc., a private holding company of various businesses and investments, including a majority interest in a publicly held manufacturing company, from 2010 to 2011; Vice President of Finance of Gevity HR, Inc., a former Nasdaq-listed professional employer organization, from 2008 to 2009; Chief Financial Officer and Secretary of Barrett Business Services, Inc., a Nasdaq-listed business services firm, from 1994 to 2008; and Executive Vice President, Chief Financial Officer and Secretary of Sprouse-Reitz Stores Inc., a former publicly held retail company, from 1988 to 1994. He began his career with Deloitte & Touche LLP. Mr. Mulholland received a B.S. in accounting and a M.B.A. in finance from the University of Oregon. He is a certified public accountant.
Richard G. Pestell, M.D., Ph.D., FRS of Medicine, M.B.A., F.A.C.P., F.R.A.C.P.
Chief Medical Officer
Dr. Richard G. Pestell is the CEO of ProstaGene, a company he founded to rapidly bring to cancer patients the benefits of novel cancer metastasis therapeutics based on targeting CCR5, and novel prostate cancer diagnostic and prognostic tests. These technologies were discovered while he was Professor and Director of the Sidney Kimmel Cancer Center at Thomas Jefferson University in Philadelphia (2005-2015). Dr. Pestell is an internationally acclaimed clinician and cancer researcher. With more than 600 published works, he is ranked by Google Scholar among the top 10 in the world for oncology, breast cancer and prostate cancer research publication citations. He has received significant national and international awards for both clinical care and cancer research, has directed two National Cancer Institute (NCI)-Designated Cancer Centers (2002-2015), and has served on the advisory board of seven NCI cancer centers, and several international research centers. Since December 2016, he has been President of the Pennsylvania Cancer and Regenerative Medicine Research Center (PCARM) and Distinguished Professor, Translational Medical Research at the Baruch S. Blumberg Institute. Dr. Pestell received his M.B.B.S. from the University of Western Australia, his M.D. and Ph.D. from the University of Melbourne and completed postdoctoral clinical and research fellowships at the Massachusetts General Hospital and Harvard Medical School. He received his Executive MBA from the Stern School of Business of New York University. From 2005 to January 2015, he was Director of the Sidney Kimmel Cancer Center and was an Executive Vice President of Thomas Jefferson University, Philadelphia. He previously served as Chairman of the Department of Oncology, Director of the Lombardi Comprehensive Cancer Center and tenured Professor at Georgetown University, Washington DC.